We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+20.73%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$498B
AUM Growth
+$25.7B
Cap. Flow
-$8.9B
Cap. Flow %
-1.79%
Top 10 Hldgs %
16.86%
Holding
2,648
New
135
Increased
1,180
Reduced
817
Closed
125

Top Buys

Rank Stock Value
1
FTV icon
Fortive
FTV
+$1.79B
2
PYPL icon
PayPal
PYPL
+$1.64B
3
BABA icon
Alibaba
BABA
+$1.46B
4
INFO
IHS Markit Ltd. Common Shares
INFO
+$1.11B
5
JCI icon
Johnson Controls International
JCI
+$1.09B

Top Sells

Rank Stock Value
1
TTE icon
TotalEnergies
TTE
+$8.15B
2
TYC
TYCO INTL PLC COM SHS (IRL)
TYC
+$1.77B
3
BMY icon
Bristol-Myers Squibb
BMY
+$1.74B
4
DHR icon
Danaher
DHR
+$1.54B
5
GE icon
GE Aerospace
GE
+$1.26B

Sector Composition

Rank Sector Weight
1 Healthcare 18.56%
2 Consumer Discretionary 15.28%
3 Financials 14.93%
4 Technology 13.43%
5 Communication Services 9.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GYRE icon
2501
Gyre Therapeutics
GYRE
$706M
$30K ﹤0.01%
219
– –
CYTR
2502
DELISTED
CytRx Corp
CYTR
$29K ﹤0.01%
8,317
– –
FNJN
2503
DELISTED
Finjan Holdings, Inc.
FNJN
$26K ﹤0.01%
15,450
– –
BONT
2504
DELISTED
Bon-Ton Stores Inc/The
BONT
$24K ﹤0.01%
14,200
– –
ACHV icon
2505
Achieve Life Sciences
ACHV
$687M
$23K ﹤0.01%
21
– –
BLFS icon
2506
BioLife Solutions
BLFS
$1.71B
$22K ﹤0.01%
+11,800
New +$22.4K
RXII
2507
DELISTED
GALENA BIOPHARMA INC COM
RXII
$21K ﹤0.01%
59,906
-994
-2% -$348
FTEK icon
2508
Fuel Tech
FTEK
$45.9M
$19K ﹤0.01%
13,700
– –
ZN
2509
DELISTED
Zion Oil & Gas, Inc.
ZN
$18K ﹤0.01%
13,100
+1,500
+13% +$2.08K
CYHHZ
2510
DELISTED
Community Health Systems, Inc. Series A Contingent Value Rights
CYHHZ
$1K ﹤0.01%
73,700
– –
FPP.WS
2511
DELISTED
FieldPoint Petroleum Corporation Common Stock Purchase Warrants
FPP.WS
$1K ﹤0.01%
46,200
– –
AER icon
2512
AerCap
AER
$23.6B
– –
-6,300
Closed -$212K
AIR icon
2513
AAR Corp
AIR
$5.96B
– –
-22,190
Closed -$518K
ALCO icon
2514
Alico
ALCO
$308M
– –
-7,310
Closed -$221K
OSG
2515
Octave Specialty Group
OSG
$210M
– –
-17,000
Closed -$280K
ANIK icon
2516
Anika Therapeutics
ANIK
$295M
– –
-5,440
Closed -$292K
ATHM icon
2517
Autohome
ATHM
$2.65B
– –
-342,256
Closed -$6.88M
ATRA icon
2518
Atara Biotherapeutics
ATRA
$83.1M
– –
-1,070
Closed -$602K
BAC.PRL icon
2519
Bank of America Series L
BAC.PRL
$4.02B
– –
-340
Closed -$405K
BKE icon
2520
Buckle
BKE
$2.33B
– –
-52,632
Closed -$1.37M
BOX icon
2521
Box
BOX
$4.48B
– –
-267,485
Closed -$2.77M
CCEP icon
2522
Coca-Cola Europacific Partners
CCEP
$47.3B
– –
-10,250
Closed -$366K
CTMX icon
2523
CytomX Therapeutics
CTMX
$760M
– –
-15,000
Closed -$153K
CVGI icon
2524
Commercial Vehicle Group
CVGI
$128M
– –
-21,000
Closed -$109K
ENVA icon
2525
Enova International
ENVA
$6.48B
– –
-25,986
Closed -$191K
99 100
101
102 103

Similar funds

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates's Q3 2016 Portfolio in Review

As of Q3 2016, T. Rowe Price Associates held 2,648 positions worth $498B, up 5.4% from $472B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

T. Rowe Price Associates's Q3 2016 filing shows 135 new, 1,180 increased, 817 reduced and 125 closed positions. Its largest new stake was Fortive: 55,770,886 shares worth $1.79B. The largest sale was TotalEnergies, an estimated $8.15B.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 20% a quarter earlier, followed by Consumer Discretionary and Financials.

  • T. Rowe Price Associates's largest Q3 2016 buy was Fortive: 55,770,886 shares worth $1.79B.
  • T. Rowe Price Associates added most to PayPal in Q3 2016, an estimated $1.64B increase.
  • T. Rowe Price Associates's biggest Q3 2016 reduction was TotalEnergies, cutting an estimated $8.15B.
  • T. Rowe Price Associates fully exited TYCO INTL PLC COM SHS (IRL) in Q3 2016, selling an estimated $1.77B.
  • T. Rowe Price Associates's ten largest holdings make up 17% of its $498B portfolio in Q3 2016.
  • T. Rowe Price Associates opened 135 new positions and closed 125 in Q3 2016.
  • T. Rowe Price Associates's portfolio value rose 5.4% quarter-over-quarter to $498B.

Based on T. Rowe Price Associates's 13F filing for Q3 2016, filed 14 Nov 2016.